Abstract 1502P
Background
Rectal cancer treatments have improved significantly over the past two decades, leading to higher survival rates. However, there's a growing emphasis on the long-term quality of life for survivors, including addressing sexual health needs. Our study aims to evaluate QOL, particularly sexual dysfunction, using validated tools like EORTC QLQ-C30, QLQ-CR29, and GRISS, aiming to improve care for rectal cancer patients.
Methods
Validated questionnaires (EORTC QLQ-C30, QLQ-CR29, GRISS) were completed by participants, assessing various aspects of quality of life and sexual satisfaction. Statistical analyses included tests for normality, descriptive analyses of patient characteristics, correlation analyses between questionnaire scores, and comparison of median scores using appropriate tests.
Results
The study included a total of 83 participants. Mean age of 55.95 ± 11.53, predominantly under 65 years (79.5%). A majority of patients (65.1%) had a stoma, and 78.3% underwent surgery, with 67.5% retaining sphincter function. The cohort was divided into non-metastatic (60.2%) and metastatic (39.8%) groups Significant correlations were observed between the Golombok Total Score and various subscores of the C30 scale. The fatigue subscore correlated positively with Golombok-female Total Score (r=0.331, p=0.041) and Golombok-male Total Score (r=0.370, p=0.042). Body image (p
Conclusions
This study demonstrates the profound and varied impact of rectal cancer treatment on patients' sexual health and overall quality of life, particularly affected by the presence of a stoma and metastatic disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1584P - Association of travel burden (TB) with colorectal cancer (CRC) outcomes in resource-limited settings (RLS)
Presenter: Saquib Banday
Session: Poster session 10
1585P - Performance status restrictions in clinical trials leading to US food and drug administration (FDA) drug approval: A cross-sectional study of a decade (2014-2023)
Presenter: Giovanni Maria Iannantuono
Session: Poster session 10
1586P - Current status of breast cancer: A comparative analysis between developed and developing countries
Presenter: Ana Isabel Martin Quesada
Session: Poster session 10
1587P - As seen through Hollywood’s lens: Cancer in movies, 2010-2020
Presenter: David Benjamin
Session: Poster session 10
1588P - Interventions to improve Herpes Zoster (HZ) vaccination rate among cancer outpatients receiving systemic treatments: A single-center real-world experience
Presenter: Sara Di Bella
Session: Poster session 10
1589P - Ramping up phase I trial recruitment: Defining potential barriers and disparities
Presenter: Burak Aktas
Session: Poster session 10
1590P - Prevalence and impact on survival of presentation to the emergency room of cancer patients: A retrospective study on real-life data
Presenter: Sonia Priou
Session: Poster session 10
1591P - Development and economic trends in new anticancer therapies licensed in the UK from 2020 to 2024
Presenter: Geetin Majhail
Session: Poster session 10
1592P - Awareness and interest of oncology professionals in sex and gender differences in cancer risk and outcome: Analysis of an ESMO Gender Medicine Task Force survey
Presenter: Berna C. Özdemir
Session: Poster session 10
1593P - Factors associated with multiple general practitioner consultations before cancer diagnosis in adolescents and young adults: A cohort study in Australia
Presenter: Jeremy Lewin
Session: Poster session 10